Table 1.

Functions of m⁶A regulators in tumor immunity

	Regulators	Cancer type	Function	References
Writers	METTL3	breast cancer	enhance PD-L1 expression	Wan et al.104
		bladder cancer	enhance PD-L1 expression	Ni et al.105
		NSCLC	reduce degradation of PD-L1	Liu et al.106
		colorectal carcinoma	reduce recruitment of CD8+ T cells and the levels of IFN-γ, CXCL9, and CXCL10	Wang et al.121
		colorectal cancer	facilitate MDSC accumulation by promoting CXCL1 expression	Chen et al.122
	RBM-15	ccRCC	increase macrophage infiltration and M2 polarization by promoting CXCL11 expression	Zeng et al.123
	METTL14	CCA	reduce degradation of PD-L1	Zheng et al.107
		HCC	enhance PD-L1 expression	Peng et al.108
		colorectal carcinoma	reduce recruitment of CD8+ T cells and the levels of IFN-γ, CXCL9, and CXCL10	Wang et al.121
Readers	IGF2BP1	HCC	enhance PD-L1 expression	Liu et al.109
	YTHDF1	colon cancer	enhance PD-L1 expression	Li et al.110
		GC	reduce DC recruitment and T cell infiltration by reducing expression of IFNGR1	Bai et al.115
	YTHDF3		downregulate PD-L1 expression	Zhao et al.113
Erasers	ALKBH5	ICC	enhance PD-L1 expression	Qiu et al.111
		melanoma/colon cancer	reduce sensitivity to immunotherapy	Li et al.118
		GBM	promote secretion of CXCL8/IL8 and recruitment of TAMs	Dong et al.124
		HCC	increase PD-L1+ macrophage recruitment	You et al.125
			Promote tumor progression by reducing RIG-I expression	Jin et al.126
	FTO	melanoma	enhance PD-1 (PDCD1), CXCR4, and SOX10 expression	Yang et al.112
		leukemia	maintain immune evasion by enhancing LILRB4 expression	Su et al.114
		melanoma	suppress infiltration and function of CD8+ T cells	Liu et al.119